Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E17.13 EPS (ttm)6.64 Insider Own0.10% Shs Outstand756.49M Perf Week-1.58%
Market Cap86.03B Forward P/E13.05 EPS next Y8.72 Insider Trans33.54% Shs Float755.64M Perf Month-5.73%
Income5.08B PEG2.25 EPS next Q1.93 Inst Own82.50% Short Float1.40% Perf Quarter-7.52%
Sales18.68B P/S4.61 EPS this Y20.30% Inst Trans0.09% Short Ratio2.74 Perf Half Y-1.23%
Book/sh29.23 P/B3.89 EPS next Y6.94% ROA8.90% Target Price132.05 Perf Year10.34%
Cash/sh25.65 P/C4.43 EPS next 5Y7.63% ROE24.20% 52W Range92.88 - 128.96 Perf YTD0.19%
Dividend2.44 P/FCF20.57 EPS past 5Y12.00% ROI10.50% 52W High-11.82% Beta0.61
Dividend %2.15% Quick Ratio3.10 Sales past 5Y4.50% Gross Margin82.10% 52W Low22.44% ATR3.73
Employees20000 Current Ratio3.40 Sales Q/Q13.30% Oper. Margin32.60% RSI (14)40.34 Volatility2.63% 2.97%
OptionableYes Debt/Eq1.45 EPS Q/Q31.70% Profit Margin27.20% Rel Volume1.58 Prev Close113.32
ShortableYes LT Debt/Eq1.34 EarningsApr 22 AMC Payout27.90% Avg Volume3.87M Price113.72
Recom2.30 SMA20-4.17% SMA50-6.69% SMA200-0.60% Volume6,107,283 Change0.35%
23-Apr-14Reiterated Oppenheimer Perform $121 → $122
21-Mar-14Reiterated Barclays Equal Weight $115 → $130
31-Jan-14Reiterated Argus Buy $130 → $135
20-Nov-13Reiterated Deutsche Bank Buy $138 → $142
29-Aug-13Reiterated UBS Buy $121 → $124
27-Aug-13Reiterated Barclays Overweight $105 → $115
31-Jul-13Reiterated Oppenheimer Perform $100 → $109
24-Apr-13Reiterated Deutsche Bank Buy $108 → $115
15-Apr-13Reiterated Barclays Equal Weight $90 → $105
08-Apr-13Reiterated RBC Capital Mkts Outperform $95 → $105
25-Jan-13Upgrade Argus Hold → Buy $96
24-Jan-13Reiterated UBS Buy $96 → $98
12-Sep-12Downgrade Robert W. Baird Outperform → Neutral $84
10-Sep-12Upgrade UBS Neutral → Buy $80 → $96
02-Aug-12Downgrade Argus Buy → Hold
15-Mar-12Resumed Stifel Nicolaus Hold
09-Feb-12Downgrade Oppenheimer Outperform → Perform
09-Sep-11Downgrade Standpoint Research Buy → Hold
10-May-11Reiterated MP Advisors Outperform $63 → $65
25-Apr-11Reiterated Stifel Nicolaus Buy $70 → $68
24-Apr-14 02:00PM  ResMed Posts In-line Earnings but Misses on Revs Zacks
10:29AM  Biotech Falls Again as Celgene Suffers at Barrons.com
09:14AM  Stock Market News for April 24, 2014 Zacks
23-Apr-14 08:18PM  Why Intuitive Surgical, Netflix, and Amgen Are Today's 3 Worst Stocks at Motley Fool -5.01%
07:02PM  Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet PR Newswire
06:32PM  3 Reasons Celgene Will Bounce Back This Year at Motley Fool
05:20PM  Encouraging Results from Pfizer's Xeljanz Zacks
04:52PM  This company just had the best new drug launch of all-time Talking Numbers
04:27PM  Amgen Revenue Misses Analysts Estimates on Enbrel Sales at Bloomberg
04:27PM  [video] The Top Ten Stocks for April 23 at Bloomberg
04:22PM  Stocks End Six-Day Win Streak As Techs Sell Off at Investor's Business Daily
03:35PM  Why Investors Are Not Chasing Gilead Endlessly Higher at 24/7 Wall St.
03:10PM  Earnings from Gilead and Amgen Put These ETFs in Focus Zacks
12:12PM  Stocks slip as earnings, disappointing home sales weighed at CNBC
12:04PM  Market Hustle: Stocks Slip After Weak China Data, Drop in U.S. Home Sales at TheStreet
11:01AM  Why Amgen (AMGN) Stock Is Down Today at TheStreet
10:28AM  Wall Street edges lower following six-day S&P rally Reuters
10:07AM  Should Amgen Break Itself Up? at Forbes
10:02AM  Amgen (AMGN) Showing Signs Of Being A Roof Leaker at TheStreet
09:08AM  [video] Cramer: Gilead crux of health care in US at CNBC
08:55AM  Stock Futures Mixed And Busy; Illumina Rockets, Cree Tumbles at Investor's Business Daily
08:40AM  Amgen's Q1 Earnings Decline Y/Y Zacks
08:36AM  Alnylam Strikes Back: Comments From CEO John Maraganore at Forbes
07:53AM  Amgen weakness a buying opportunity, says Cowen theflyonthewall.com
05:00AM  'Fast Money' Recap: Riding the Momentum at TheStreet
02:17AM  Centene (CNC) Soars: Stock Adds 12.2% in Session Zacks
12:41AM  Amgen's CEO Discusses Q1 2014 Results - Earnings Call Transcript Seeking Alpha
22-Apr-14 10:05PM  Amgen Posts Lower-Than-Expected Earnings at New York Times
10:05PM  Amgen Posts Lower-Than-Expected Earnings at New York Times
07:13PM  Amgen misses 1Q views as higher costs cut profit AP
07:09PM  [$$] Amgen Profit Falls 25% at The Wall Street Journal
06:34PM  New Drugs Help Drive Amgen's Operating Income Up 18% in Q1 at Motley Fool
06:02PM  Amgen profit falls on inventory draw downs; sales disappoint Reuters
05:55PM  Gilead shares climb; AT&T, Amgen shares fall at MarketWatch
05:23PM  Amgen misses 1Q views as higher costs cut profit AP
05:15PM  Amgen Earnings Call scheduled for 5:15 pm ET today CCBN
05:05PM  Gilead shares climb; AT&T, Amgen shares fall at MarketWatch
05:04PM  Amgen earnings down 25% as costs rise at MarketWatch
04:50PM  The closest thing to a sure thing for you and your money at MarketWatch
04:48PM  An Earnings Tale of Two Biotechs Gilead vs. Amgen 24/7 Wall St.
04:40PM  Amgen earnings down 25% as costs rise at MarketWatch
04:39PM  Amgen misses 1Q views as higher costs cut profit AP
04:34PM  [$$] Amgen Profit Falls 25% at The Wall Street Journal
04:32PM  Amgen says total product sales declined 9% sequentially in Q1 at theflyonthewall.com
04:26PM  Amgen Falls as Earnings, Revenue Disappoint at Barrons.com
04:24PM  Earnings and big pharma deals drive stocks up Hot Stock Minute
04:15PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:13PM  Amgen revenue misses analyst estimates at Los Angeles Times
04:13PM  Amgen profit falls on costs, disappointing sales Reuters
04:09PM  Amgen earnings, sales come in below estimates at MarketWatch
04:06PM  [video] Amgen Q1 earnings miss at CNBC
04:04PM  Amgen Revenue Misses Analysts Estimates on Enbrel Sales at Bloomberg
04:03PM  Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion PR Newswire
03:52PM  AT&T, Yum Brands set for after-hours action at MarketWatch
03:45PM  Sarepta Soars on Eteplirsen Submission Plans Zacks
02:35PM  Earnings Preview: Amgen's timeline for Evolocumab will be in focus at theflyonthewall.com
02:12PM  AT&T, Yum Brands set for after-hours action at MarketWatch
01:07PM  [video] Biggest biotech players at CNBC
08:47AM  Amgen Versus Celgene: Value/Growth Face Off at Seeking Alpha
07:34AM  Amgen Earnings Call scheduled for 5:15 pm ET today CCBN
07:07AM  Q1 2014 Amgen Earnings Release - After Market Close CCBN
03:51AM  Pfizer, AstraZeneca Are Ripe for Pharma Deal: Real M&A Bloomberg
03:51AM  Pfizer, AstraZeneca Are Ripe for Pharma Deal Alone or Together Bloomberg
21-Apr-14 06:34PM  What to Watch for in Biotech Earnings This Week at Motley Fool
05:41PM  Value stocks to stay in vogue, as momentum fades at CNBC
05:20PM  Will Amgen (AMGN) Miss This Earnings Season? Zacks
04:48PM  Retail Investors Should Be Doing Valuations On Their Biotechs - The Market Is at Seeking Alpha
03:54PM  [video] Earnings crystal ball at CNBC
02:34PM  Biotech Is Not A Popping Bubble: Buy The Dip While You Can at Seeking Alpha
02:09PM  Another Technical Look at the Big Biotech ETF ETF Trends
12:20PM  Can Gilead's Sovaldi rescue biotech? at CNBC
18-Apr-14 12:12PM  Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings at Investor's Business Daily
17-Apr-14 05:03PM  FDA Grants Fast Track Status To Amgen Heart Failure Drug at Forbes
04:10PM  Emergent BioSolutions Gains on Trial News Zacks
04:05PM  Amgen Announces Webcast of 2014 First Quarter Financial Results PR Newswire
02:34PM  A Real Dividend Growth Machine: Q1 2014 Review at Seeking Alpha
01:22PM  [video] Kudlow: Two economic cycles at CNBC
09:32AM  Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc. at Motley Fool
16-Apr-14 03:10PM  Dynavax Starts Phase III Study on Heplisav-B Zacks
05:00AM  'Fast Money' Recap: Impressed by Yahoo! at TheStreet
15-Apr-14 04:23PM  Nasdaq rides biggest trading rollercoaster in five years at CNBC
04:20PM  Encouraging Results from Lexicon Candidate Zacks
02:03PM  Capitulation or correction? Nasdaq nears 10% drop at CNBC
01:19PM  Another Earnings Beat from J&J, View Up Zacks
12:40PM  [video] Love biotech on correction: Trader at CNBC
12:37PM  [video] Top biotech analyst forecasts bottom at CNBC
06:49AM  Ambit Biosciences Slumps: AMBI Falls 13.0% in Session Zacks
05:00AM  'Fast Money' Recap: Long on Financials at TheStreet
14-Apr-14 06:14PM  Amgen's Conundrum at Motley Fool
03:30PM  Positive Results on Intercept Pharma's OCA Zacks
10:30AM  Gilead Bucks Biotech Trend Thanks to Sovaldi News Zacks
10:05AM  Momentum Investing: When Leaders Become Laggards at Barrons.com
07:43AM  [video] Pro picks Gannett, Amgen & more at CNBC
12-Apr-14 12:01AM  [$$] The Highfliers Are Still Too High at Barrons.com
11-Apr-14 02:32PM  Are Celgene and Amgen Undervalued By the Market? at Motley Fool
08:42AM  [video] Here's what's pushing biotech lower: Expert at CNBC
08:32AM  3 Biotech Companies That Look To Be Good Buys After A Pullback at Seeking Alpha
12:06AM  This is the make-or-break level for biotech Talking Numbers
10-Apr-14 03:39PM  Gilead Announces Encouraging Sovaldi Data Zacks
03:37PM  Biotech: Like Lambs to the Slaughter at Barrons.com
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM
AMGEN INC10% OwnerDec 17Buy7.00272,1421,904,994541,399Dec 18 06:09 PM
Balachandran MadhavanEVP, OperationsSep 04Option Exercise58.4318,0001,051,74059,133Sep 05 07:33 PM
Balachandran MadhavanEVP, OperationsSep 04Sale112.7618,0002,029,76834,851Sep 05 07:33 PM
BALTIMORE DAVIDDirectorAug 28Sale109.664,582502,46227,789Aug 30 05:36 PM
Amgen Ventures LLC10% OwnerJun 05Buy15.0016,666249,990334,126Jun 05 04:01 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 22Option Exercise54.626,130334,79122,863May 24 05:18 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 22Sale104.786,130642,29616,733May 24 05:18 PM
Balachandran MadhavanEVP, OperationsMay 21Option Exercise50.446,000302,64046,956May 21 08:18 PM
Balachandran MadhavanEVP, OperationsMay 21Sale103.286,000619,68134,851May 21 08:18 PM
HENDERSON REBECCA MDirectorMay 17Option Exercise55.767,000390,31013,898May 20 07:15 PM
HENDERSON REBECCA MDirectorMay 17Sale105.728,421890,3005,477May 20 07:15 PM
Patton Cynthia MSVP & CCOMay 16Option Exercise54.583,544193,43718,986May 17 05:42 PM
Patton Cynthia MSVP & CCOMay 16Sale105.013,544372,14815,442May 17 05:42 PM
BIONDI FRANKDirectorMay 14Option Exercise56.5010,000564,95039,780May 16 05:38 PM
PELHAM JUDITH CDirectorMay 14Option Exercise55.4725,0001,386,65048,149May 16 05:42 PM
PELHAM JUDITH CDirectorMay 14Sale108.2525,0002,706,16523,149May 16 05:42 PM
BIONDI FRANKDirectorMay 14Sale108.4310,0001,084,31829,780May 16 05:38 PM
de Carbonnel FrancoisDirectorApr 30Option Exercise54.7410,000547,40021,930May 02 06:26 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 29Option Exercise50.4410,000504,40064,643Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 29Sale107.0210,0001,070,19154,643Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 26Option Exercise58.4310,000584,30066,077Apr 30 05:21 PM
MCNAMEE BRIAN MSVP, Human ResourcesApr 26Sale107.9910,0001,079,87256,077Apr 30 05:21 PM